

## DAFTAR PUSTAKA

- Aghamohammad S, Sepehr A, Miri ST, Najafi S, Rohani M, Pourshafiea MR. (2022). The effects of the probiotic cocktail on modulation of the NF-kB and JAK/STAT signaling pathways involved in the inflammatory response in bowel disease model. *BMC Immunol*, 23(1):8. doi:10.1186/s12865-022-00484-6
- Agraib, L. M., Al-Shorman, A., Salah, S., Abu-Hijlih, R., & Abuhijla, F. (2020). The effect of probiotics supplementation on the side effects of chemoradiotherapy for colorectal cancer: A literature review. *Onkologia i Radioterapia*, 14(4), 1–9.
- Aindelis, G., & Chlichlia, K. (2020). Modulation of anti-tumour immune responses by probiotic bacteria. *Vaccines*, 8(2), 1–17. <https://doi.org/10.3390/vaccines8020329>
- Akgul A, Maddaloni M, Jun SM, Nelson AS, Odreman VA, Hoffman C, Bhagyaraj E, Voigt A, Abbott JR, Nguyen CQ, Pascual DW. (2021). Stimulation of regulatory T cells with *Lactococcus lactis* expressing enterotoxigenic *E. coli* colonization factor antigen 1 retains salivary flow in a genetic model of Sjögren's syndrome. *Arthritis Res Ther*, 23(1), 99.
- American Cancer Society. (2020). *Colorectal Cancer Facts & Figures 2020-2022*. Atlanta, GA. Available from: <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2020-2022.pdf>
- Andhika, O. (2015). Phytopreventive Effect of Buah Merah (*Pandanus conoideus* Lam.) Oil in Colitis-Associated Carcinogenesis. *Journal Of Medicine & Health*, 1(2). doi:10.28932/jmh.v1i2.508.
- Arifin, W. N., & Zahiruddin, W. M. (2017). Sample size calculation in animal studies using resource equation approach. *Malaysian Journal of Medical Sciences*, 24(5), 101–105. <https://doi.org/10.21315/mjms2017.24.5.11>
- Arnold, M., Sierra, M. S., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2017). Global patterns and trends in colorectal cancer incidence and mortality. *Gut*, 66(4), 683–691. <https://doi.org/10.1136/gutjnl-2015-310912>
- Aubry C, Michon C, Chain F, Chvatchenko Y, Goffin L, Zimmerli SC, et al. (2015). Protective effect of TSLP delivered at the gut mucosa level by recombinant lactic acid bacteria in DSS-induced colitis mouse model. *Microb Cell Fact*, 14(1):1–10.
- Avallone, A., Delrio, P., Pecori, B., Tatangelo, F., Petrillo, A., Scott, N., Marone, P., Aloï, L., Sandomenico, C., Lastoria, S., Iaffaioli, V. R., Scala, D., Iodice, G., Budillon, A., & Comella, P. (2011). Oxaliplatin plus dual inhibition of thymidilate synthase during preoperative pelvic radiotherapy for locally advanced rectal carcinoma: Long-term outcome. *Int J Radiat Oncol Biol Phys*, 79(3), 670–6.
- Baek, S. K., Carmichael, J. C., & Pigazzi, A. (2006).

- Robotic Surgery: Colon and Rectum. *Controv Laparosc Surg*, 19(2), 127–33.
- Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J and Klein B (1995): Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. *Blood* 86: 685-691.
- Beets-Tan, R., Lambregts, D., Maas, M., Bipat, S., Barbaro, B., Curvo-Semedo, L., Fenlon, H. M., Gollub, M. J., Gourtsoyianni, S., Halligan, S., Hoeffel, C., Kim, S. H., Laghi, A., Maier, A., Rafaelsen, S. R., Stoker, J., Taylor, S. A., Torkzad, M. R., & Blomqvist, L. (2018). Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. *Eur Radiol*, 28(4), 1465–75.
- Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y. J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Engstrom, P. F., Garrido-Laguna, I., Grem, J. L., Grothey, A., Hochster, H. S., Hoffe, S., Hunt, S., Kamel, A., Kirilcuk, N., Krishnamurthi, S., Messersmith, W. A., Miller, E. D., Mulcahy, M. F., Murphy, J. D., Nurkin, S., Saltz, L., Sharma, S., Shibata, D., Skibber, J. M., Sofocleous, C. T., Stoffel, E. M., Stotsky-Himelfarb, E., Willett, C. G., Wuthrick, E., Gregory, K. M., & Freedman-Cass, D. A. (2018). NCCN Guidelines Insights: Colon Cancer, Version 2.2018. *Journal of the National Comprehensive Cancer Network : JNCCN*, 16(4), 359–369.
- Berding, K., Vlckova, K., Marx, W., Schellekens, H., Stanton, C., Clarke, G., Jacka, F., Dinan, T. G., & Cryan, J. F. (2021). Diet and the Microbiota-Gut-Brain Axis: Sowing the Seeds of Good Mental Health. *Advances in nutrition (Bethesda, Md.)*, 12(4), 1239–1285.
- Bertero, L., Castellano, I., Metovic, J., & Ricardi, U. (2018). Eight edition of the UICC classification of malignant tumours: an overview of the changes in the pathological TNM classification criteria-what has changed and why?. *Virchow Archiv*, 472, 519-31.
- Borowczak J, Szczerbowski K, Maniewski M, Kowalewski A, Janiczek-Polewska M, Szyłberg A, et al. (2022). The Role of Inflammatory Cytokines in the Pathogenesis of Colorectal Carcinoma—Recent Findings and Review. *Biomedicines*, 10(7).
- Bopanna S, Kedia S, Das P, Dattagupta S, Sreenivas V, Mouli VP, Dhingra R, Pradhan R, Kumar NS, Yadav DP, Makharia G, & Ahuja V. (2017). Long-term follow-up reveals high incidence of colorectal cancer in Indian patients with inflammatory bowel disease. *United European gastroenterology journal* 5 (5): 708–714. <https://doi.org/10.1177/2050640616680552>
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 68(6), 394–424. <https://doi.org/10.3322/caac.21492>

- Brzacki, V., Nagorni, A., Kallistratos, M. et al. (2019). Diabetes Mellitus: a Clinical Condition Associated with Metabolic Syndrome and Colorectal Cancer Risk. *Curr Pharmacol Rep* 5, 205–209. <https://doi.org/10.1007/s40495-019-00183-8>
- Bujko, K., Nowacki, M. P., Nasierowska-Guttmejer, A., Michalski, W., Bebenek, M., & Kryj, M. (2006). Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. *Br J Surg*, 93(10), 1215–23.
- Campos, G. M., Américo, M. F., Dos Santos Freitas, A., Barroso, F. A. L., da Cruz Ferraz Dutra, J., Quaresma, L. S., Cordeiro, B. F., Laguna, J. G., de Jesus, L. C. L., Fontes, A. M., Birbrair, A., Santos, T. M., & Azevedo, V. (2024). Lactococcus lactis as an Interleukin Delivery System for Prophylaxis and Treatment of Inflammatory and Autoimmune Diseases. *Probiotics and antimicrobial proteins*, 16(2), 352–366. <https://doi.org/10.1007/s12602-023-10041-1>
- Carethers, J. M., Smith, E. J., Behling, C. A., Nguyen, L., Tajima, A., Doctolero, R. T., Cabrera, B. L., Goel, A., Arnold, C. A., Miyai, K., & Boland, C. R. (2004). Use of 5-Fluorouracil and Survival in Patients with Microsatellite-Unstable Colorectal Cancer. *Gastroenterology*, 126(2), 394–401.
- Carethers, J. M., & Doubeni, C. A. (2020). Causes of Socioeconomic Disparities in Colorectal Cancer and Intervention Framework and Strategies. *Gastroenterology*, 158(2), 354–367. <https://doi.org/10.1053/j.gastro.2019.10.029>
- Chauhan, A., Singh R., 2019 Probiotic in aquaculture: a promising emerging alternative approach. *Symbiosis*, 77,99-113.
- Chen C, Li H. (2020). The Inhibitory Effect of Gut Microbiota and Its Metabolites on Colorectal Cancer. *J Microbiol Biotechnol*, 30(11), 1607-1613.
- Cheng, Y., Ling, Z., & Li, L. (2020). The Intestinal Microbiota and Colorectal Cancer. *Frontiers in immunology*, 11, 615056. <https://doi.org/10.3389/fimmu.2020.615056>
- Chiabai MJ, Almeida JF, de Azevedo MGD, Fernandes SS, Pereira VB, de Castro RJA, Jerônimo MS, Sousa IG, de Souza Vianna LM, Miyoshi A, Bocca AL, Maranhão AQ, Brigido MM. (2019). Mucosal delivery of Lactococcus lactis carrying an anti-TNF scFv expression vector ameliorates experimental colitis in mice. *BMC Biotechnol*, 19(1), 38.
- Ciccolallo, L., Capocaccia, R., Coleman, M. P., Berrino, F., Coebergh, J. W. W., Damhuis, R. A., Faivre, J., Martinez-Garcia, C., Møller, H., Ponz de Leon, M., Launoy, G., Raverdy, N., Williams, E. M., Gatta, G. (2005). Survival differences between European and US patients with colorectal cancer: Role of stage at diagnosis and surgery. *Gut*, 54(2), 268–73.
- Compton, C. C., & Greene, F. L. (2004). The Staging of Colorectal Cancer: 2004 and Beyond. *Cancer J Clin*, 54(6), 295–308.

- Coker OO, Nakatsu G, Dai RZ, Wu WKK, Wong SH, Ng SC, et al. 2019. Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer. *Gut*, 68:654–62.
- Corley, D. A., Jensen, C. D., Marks, A. R., Zhao, W. K., Lee, J. K., Doubeni, C. A., Zauber, A. G., de Boer, J., Fireman, B. H., Schottinger, J. E., Quinn, V. P., Ghai, N. R., Levin, T. R., & Quesenberry, C. P. (2014). Adenoma Detection Rate and Risk of Colorectal Cancer and Death. *N Engl J Med*, 370(14), 1298–306.
- Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M., & Wallace, M. B. (2019). Colorectal cancer. *Lancet*, 394(10207), 1467–80. Available from: [http://dx.doi.org/10.1016/S0140-6736\(19\)32319-0](http://dx.doi.org/10.1016/S0140-6736(19)32319-0)
- De Rosa, M., Pace, U., Rega, D., Costabile, V., Duraturo, F., Izzo, P., & Delrio, P. (2015). Genetics, diagnosis and management of colorectal cancer (Review). *Oncol Rep*, 34(3), 1087–96.
- Dikeocha, I. J., Al-Kabsi, A. M., Hussin, S., & Alshawsh, M. A. (2020). Role of probiotics in patients with colorectal cancer: A systematic review protocol of randomised controlled trial studies. *BMJ Open*, 10(8), 1–5. <https://doi.org/10.1136/bmjopen-2020-038128>
- Djaldetti M, Bessler H. (2017). Probiotic strains modulate cytokine production and the immune interplay between human peripheral blood mononuclear cells and colon cancer cells. *FEMS Microbiol Lett*, 364(3).
- Dommels, Y. E. M., Kemperman, R. A., Zebregs, Y. E. M. P., Draaisma, R. B., Jol, A., Wolvers, D. A. W., Vaughan, E. E., & Albers, R. (2009). Survival of *Lactobacillus reuteri* DSM 17938 and *Lactobacillus rhamnosus* GG in the human gastrointestinal tract with daily consumption of a low-fat probiotic spread. *Applied and Environmental Microbiology*, 75(19), 6198–6204. <https://doi.org/10.1128/AEM.01054-09>
- Drago, L. (2019). Probiotics and colon cancer. *Microorganisms*, 7(3), 1–11. <https://doi.org/10.3390/microorganisms7030066>
- Ellis, L., Abrahão, R., McKinley, M., Yang, J., Somsouk, M., Marchand, L. L., Cheng, I., Gomez, S. L., & Shariff-Marco, S. (2018). Colorectal Cancer Incidence Trends by Age, Stage, and Racial/Ethnic Group in California, 1990-2014. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 27(9), 1011–1018.
- Ericsson, A. C., Akter, S., Hanson, M. M., Busi, S. B., Parker, T. W., Schehr, R. J., Hankins, M. A., Ahner, C. E., Davis, J. W., Franklin, C. L., Amos-Landgraf, J. M., & Bryda, E. C. (2015). Differential susceptibility to colorectal cancer due to naturally occurring gut microbiota. *Oncotarget*, 6(32), 33689–704.

- Fan M, Zhang Z, Ruan G, et al. (2021). *Bacteroides fragilis* controls intestinal inflammation through promoting Treg differentiation via TGF- $\beta$ /Smad3 signaling pathway. Research Square. DOI: 10.21203/rs.3.rs-444129/v1.
- Fareez I, Haque N, Mohammed Al-Namnam N, Yuan Seng W, Shafiq A, Izwan Ismail M, Siong Meng L, Kalavathy R. (2023). Dysbiosis and the Chemopreventive Role of Prebiotics in Colorectal Cancer. *Journal of Applied Biotechnology Reports*, 10(2), 943-957.
- Flemer, B., Lynch, D. B., Brown, J. M., Jeffery, I. B., Ryan, F. J., Claesson, M. J., O'Riordain, M., Shanahan, F., & O'Toole, P. W. (2017). Tumour-associated and non-tumour-associated microbiota in colorectal cancer. *Gut*, 66(4), 633–43.
- Frigerio S, Lartey DA, D'Haend GR, & Grootjans J. (2021). The Role of the Immune System in IBD- Associated Colorectal Cancer: From Pro to Anti Tumorigenic Mechanisms. *Int J Moel*, 22, 12739.
- Ghosh, S., & Hayden, M. (2008). New regulators of NF- B in inflammation. *Nature Rev Immunol*, 8, 837-848.
- Grivennikov SI, Cominelli F. Colitis-associated and sporadic colon cancers: different diseases, different mutations? *Gastroenterology*. 2016;150(4):808–10
- Gryfe, R., Kim, H., Hsieh, E. T., Aronson, M. D., Holowaty, E. J., Bull, S. B., Redston, M., & Gallinger, S. (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. *N Engl J Med*, 342, 69–77.
- Ha S, Zhang X, Yu J. (2024). Probiotics intervention in colorectal cancer: From traditional approaches to novel strategies. *Chin Med J (Engl)*, 137(1), 8-20.
- Haghshenas, B., Abdullah, N., Nami, Y., Radiah, D., Rosli, R., & Khosroushahi, A. Y. (2014). Different effects of two newly-isolated probiotic *Lactobacillus plantarum* 15HN and *Lactococcus lactis* Lactis 44Lac strains from traditional dairy products on cancer cell lines. *Anaerobe*, 30, 51–59.
- Han, K. J., Lee, N. K., Park, H., & Paik, H. D. (2015). Anticancer and Anti-Inflammatory Activity of Probiotic *Lactococcus lactis* NK34. *Journal of microbiology and biotechnology*, 25(10), 1697–1701.
- Han, J., Xi, Q., Meng, Q., Liu, J., Zhang, Y., Han, Y., Zhuang, Q., Jiang, Y., Ding, Q., & Wu, G. (2016). Interleukin-6 promotes tumor progression in colitis-associated colorectal cancer through HIF-1 $\alpha$  regulation. *Oncology Letters*, 12(6), 4665–4670. <https://doi.org/10.3892/ol.2016.5227>
- Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. *Cell*, 44(5), 46-74. doi: 10.1016/j.cell.2011.02.013.
- Hasan, N., & Yang, H. (2019). Factors affecting the composition of the gut microbiota, and its modulation. *PeerJ*, 7, e7502.

- Hendler, R., & Zhang, Y. (2018). Probiotics in the Treatment of Colorectal Cancer. *Medicines (Basel)*, 5(3), 101.
- Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA. (2019). The microbiome, cancer, and cancer therapy. *Nat Med*, 25, 377–8
- Heo G, Lee Y, Im E. (2021). Interplay between the Gut Microbiota and Inflammatory Mediators in the Development of Colorectal Cancer. *Cancers (Basel)*, 13(4), 734.
- Hirano, T., Hirayama, D., Wagatsuma, K., Yamakawa, T., Yokoyama, Y., & Nakase, H. (2020). Immunological Mechanisms in Inflammation-Associated Colon Carcinogenesis. *International journal of molecular sciences*, 21(9), 3062. <https://doi.org/10.3390/ijms21093062>
- Hnatyszyn, A., Hryhorowicz, S., Kaczmarek-Ryś, M., Lis, E., Słomski, R., Scott, R. J., & Pławski, A. (2019). Colorectal carcinoma in the course of inflammatory bowel diseases. *Hereditary cancer in clinical practice*, 17, 18. <https://doi.org/10.1186/s13053-019-0118-4>
- Hohenberger, W., Weber, K., Matzel, K., Papadopoulos, T., & Merkel, S. (2009). Standardized surgery for colonic cancer: Complete mesocolic excision and central ligation - Technical notes and outcome. *Color Dis*, 11(4), 354–64.
- Hossain, M. S., Karuniawati, H., Jairoun, A. A., Urbi, Z., Ooi, J., John, A., Lim, Y. C., Kibria, K. M. K., Mohiuddin, A. K. M., Ming, L. C., Goh, K. W., & Hadi, M. A. (2022). Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. *Cancers*, 14(7), 1732. <https://doi.org/10.3390/cancers14071732>
- Howe, J. R., & Guillem, J. G. (1997). The genetics of colorectal cancer. *Surg Clin North Am*, 77(1), 175–9.
- Hradicka P, Beal J, Kassayova M, Foey A, Demeckova V. (2020). A Novel Lactic Acid Bacteria Mixture: Macrophage-Targeted Prophylactic Intervention in Colorectal Cancer Management. *Microorganisms*, 8(3), 387.
- Hu, Y., Xiang, J., Su, L., & Tang, X. (2020). The regulation of nitric oxide in tumor progression and therapy. *The Journal of international medical research*, 48(2), 300060520905985.
- Hua, S. (2019). Physiological and Pharmaceutical Consideration for Rectal Drug Formulation. *Front Pharmacol*, 10, 1196
- Huang, J., Papadopoulos, N., McKinley, A. J., Farrington, S. M., Curtis, L. J., Wyllie, A. H., Zheng, S., Willson, J. K., Markowitz, S. D., Morin, P., Kinzler, K. W., Vogelstein, B., & Dunlop, M. G. (1996). APC mutations in colorectal tumors with mismatch repair deficiency. *Proc Natl Acad Sci U S A*, 93(17), 9049–54.
- Ihara S, Hirata Y, Koike K. (2017). TGF- $\beta$  in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota. *J Gastroenterol*, 52(7), 777–87.

- Itatani Y, Kawada K, Sakai Y. (2019). Transforming Growth Factor- $\beta$  Signaling Pathway in Colorectal Cancer and Its Tumor Microenvironment. *Int J Mol Sci*, 20(23), 5822.
- Jackson DN, Theiss AL. (2020). Gut bacteria signaling to mitochondria in intestinal inflammation and cancer. *Gut Microbes*, 11(3), 285-304.
- Jass, J. R., Young, J., & Leggett, B. A. (2002). Evolution of colorectal cancer: Change of pace and change of direction. *J Gastroenterol Hepatol*, 17(1), 17–26.
- Jeon HJ, Yeom Y, Kim YS, Kim E, Shin JH, Seok PR, Woo MJ, Kim Y. (2018). Effect of vitamin C on azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated early colon cancer in mice. *Nutr Res Pract*, 12(2), 101-109.
- Kaczmarek, K., Więckiewicz, J., Węglarczyk, K., Siedlar, M., & Baran, J. (2021). The Anti-Tumor Effect of Lactococcus lactis Bacteria-Secreting Human Soluble TRAIL Can Be Enhanced by Metformin Both In Vitro and In Vivo in a Mouse Model of Human Colorectal Cancer. *Cancers*, 13(12), 3004. <https://doi.org/10.3390/cancers13123004>
- Kahouli I, Tomaro-Duchesneau C, Prakash S. (2013). Probiotics in colorectal cancer (CRC) with emphasis on mechanism of action and current perspectives. *Journal of medical microbiology*, 62, 1107-1123.
- Kameyama, H., Nagahashi, M., Shimada, Y., Tajima, Y., Ichikawa, H., Nakano, M., Sakata, J., Kobayashi, T., Narayanan, S., Takabe, K., & Wakai, T. (2018). Genomic characterization of colitis-associated colorectal cancer. *World Journal of Surgical Oncology*, 16(1), 4–9. <https://doi.org/10.1186/s12957-018-1428-0>
- Kang, S. B., Park, J. W., Jeong, S. Y., Nam, B. H., Choi, H. S., Kim, D. W., Lim, S. B., Lee, T. G., Kim, D. Y., Kim, J. S., Chang, H. J., Lee, H. S., Kim, S. Y., Jung, K. H., Hong, Y. S., Kim, J. H., Sohn, D. K., Kim, D. H., & Oh, J. H. (2010). Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): Short-term outcomes of an open-label randomised controlled trial. *Lancet Oncol*, 11(7), 637–45. [http://dx.doi.org/10.1016/S1470-2045\(10\)70131-5](http://dx.doi.org/10.1016/S1470-2045(10)70131-5)
- Karin, M., & Greten, F. R. (2005). NF- $\kappa$ B linking inflammation and immunity to cancer development and progression. *Nature Rev Immunol*, 5, 749-759.
- Kasai, C., Sugimoto, K., Moritani, I., Tanaka, J., Oya, Y., Inoue, H., Tameda, M., Shiraki, K., Ito, M., Takei, Y., & Takase, K. (2016). Comparison of human gut microbiota in control subjects and patients with colorectal carcinoma in adenoma: Terminal restriction fragment length polymorphism and next-generation sequencing analyses. *Oncol Rep*, 35(1), 325–33.
- Keller, D. S., Windsor, A., Cohen, R., & Chand, M. (2019). Colorectal cancer in inflammatory bowel disease: review of the evidence. *Techniques in coloproctology*, 23(1), 3–13. <https://doi.org/10.1007/s10151-019-1926-2>

- Kemenkes RI. (2016). Panduan Penatalaksanaan Kanker kolorektal. Kementerian Kesehatan Republik Indonesia, 76.
- Keum, N., & Giovannucci, E. (2019). Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. *Nature reviews. Gastroenterology & hepatology*, 16(12), 713–732.
- Kheirelseid, E. A. H., Miller, N., & Kerin, M. J. (2013). Molecular biology of colorectal cancer: Review of the literature. *Am J Mol Biol*, 3(2), 72-80.
- Kim, M. A., Lee, H. E., Lee, H. S., Yang, H. K., & Kim, W. H. (2011) Expression of apoptosis-related proteins and its clinical implication in surgically resected gastric carcinoma. *Virchows Arch*, 459(5), 503–10.
- Konishi, M., Kikuchi-Yanoshita, R., Tanaka, K., Muraoka, M., Onda, A., Okumura, Y., Kishi, N., Iwama, T., Mori, T., Koike, M., Ushio, K., Chiba, M., Nomizu, S., Konishi, F., Utsunomiya, J., & Miyaki, M. (1996). Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. *Gastroenterology*, 111(2), 307–17.
- Kwok, K. O., Fries, L. R., Silva-Zolezzi, I., Thakkar, S. K., Iroz, A., & Blanchard, C. (2022). Effects of Probiotic Intervention on Markers of Inflammation and Health Outcomes in Women of Reproductive Age and Their Children. *Frontiers in nutrition*, 9, 889040.
- Labianca, R., Nordlinger, B., Beretta, G. D., Mosconi, S., Mandalà, M., Cervantes, A., Arnold, D., & ESMO Guidelines Working Group. (2013). Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 24 Suppl 6, vi64-vi72.
- Lane, D. P. (1993). A death in the life of p53. *Nature*, 362(6423), 786–7.
- Lanspa, S. J., Lynch, H. T., & Bleeding, V. (2010). Correspondence Quality Indicators for Colonoscopy and the Risk of Interval Cancer. *N Engl J Med*, 363(14), 1371–3.
- Lanza, G., Gafà, R., Santini, A., Maestri, I., Guerzoni, L., & Cavazzini, L. (2006). Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. *J Clin Oncol*, 24(15), 2359–67.
- Lee, N. K., Han, K. J., Son, S. H., Eom, S. J., Lee, S. K., & Paik, H. D. (2015). Multifunctional effect of probiotic *Lactococcus lactis* KC24 isolated from kimchi. *LWT - Food Science and Technology*, 64(2), 1036–1041.
- Lee J, Kim S, Kang CH. (2022). Immunostimulatory Activity of Lactic Acid Bacteria Cell-Free Supernatants through the Activation of NF- $\kappa$ B and MAPK Signaling Pathways in RAW 264.7 Cells. *Microorganisms*, 10(11):2247. doi: 10.3390/microorganisms10112247



- Lee SY, Lee DY, Kang JH, Kim JH, Jeong JW, Kim HW, Oh DH, Yoon SH, Hur SJ. (2022). Relationship between gut microbiota and colorectal cancer: Probiotics as a potential strategy for prevention. *Food Res Int*, 156:111327.
- Levine, A. J. (1997). p53, the Cellular Gatekeeper for Growth and Division. *Cell*, 88(5), 323–31.
- Li C, Lau HC, Zhang X, Yu J. (2022). Mouse Models for Application in Colorectal Cancer: Understanding the Pathogenesis and Relevance to the Human Condition. *Biomedicines*, 10(7):1710.
- Li, S., Konstantinov, S. R., Smits, R., & Peppelenbosch, M. P. (2017). Bacterial Biofilms in Colorectal Cancer Initiation and Progression. *Trends Mol Med*, 23(1), 18–30. <http://dx.doi.org/10.1016/j.molmed.2016.11.004>
- Lin Y, He Z, Ye J, Liu Z, She X, Gao X, Liang R. (2020). Progress in Understanding the IL-6/STAT3 Pathway in Colorectal Cancer. *Onco Targets Ther*, 13:13023-13032.
- Liu T, Zhang L, Joo D, Sun SC. (2017). NF- $\kappa$ B signaling in inflammation. *Signal Transduct Target Ther*, 2:17023-. doi:10.1038/sigtrans.2017.23
- Liu J, Wang S, Yi R, Long X, Zhao X. (2022). Effect of *Lactobacillus fermentum* ZS40 on the NF- $\kappa$ B signaling pathway in an azomethane-dextran sulfate sodium-induced colon cancer mouse model. *Front Microbiol*, 13:953905.
- Luerce, T. D., Gomes-Santos, A. C., Rocha, C. S., Moreira, T. G., Cruz, D. N., Lemos, L., Sousa, A. L., Pereira, V. B., de Azevedo, M., Moraes, K., Cara, D. C., LeBlanc, J. G., Azevedo, V., Faria, A. M. C., & Miyoshi, A. (2014). Anti-inflammatory effects of *Lactococcus lactis* NCDO 2118 during the remission period of chemically induced colitis. *Gut pathogens*, 6, 33. <https://doi.org/10.1186/1757-4749-6-33>
- Luo C, Zhang H. (2017). The role of proinflammatory pathways in the pathogenesis of colitis-associated colorectal cancer. *Mediators of Inflammation*, 2017, 5126048. doi:10.1186/2017/5126048.
- Memon, S., Heriot, A. G., Murphy, D. G., Bressel, M., & Lynch, A. C. (2012). Robotic versus laparoscopic proctectomy for rectal cancer: A meta-analysis. *Ann Surg Oncol*, 19(7), 2095–101.
- Middleton K, Jones J, Lwin Z & Coward JI. (2014). Interleukin-6: An angiogenic target in solid tumours. *Crit Rev Oncol Hematol* 89: 129-139.
- Milajerdi, A., Mousavi, S. M., Sadeghi, A., Salari-Moghaddam, A., Parohan, M., Larijani, B., & Esmailzadeh, A. (2020). The effect of probiotics on inflammatory biomarkers: a meta-analysis of randomized clinical trials. *European journal of nutrition*, 59(2), 633–649.
- Molska M, Reguła J. (2019). Potential Mechanisms of Probiotics Action in the Prevention and Treatment of Colorectal Cancer. *Nutrients*, 11(10):2453.

- National Collaborating Centre for Cancer. (2015) Suspected Cancer: Recognition and Referral [Internet]. NG 12. NICE Guidelines. London: [Updated 2020 Sept; cited 2021 Jan 20]. Available from: <https://www.nice.org.uk/guidance/ng12>
- Mendes MCS, Paulino DS, Brambilla SR, Camargo JA, Persinoti GF, Carvalheira JBC. (2018). Microbiota modification by probiotic supplementation reduces colitis associated colon cancer in mice. *World J Gastroenterol*, 4(18):1995-2008.
- Mills, S., Ross, R.P., & Coffey, A. (2011). Lactic Acid Bacteria: *Lactococcus lactis*. In *Encyclopedia of Dairy Science*, 2nd Edition. Eds: John W. Fuquay, Patrick F. Fox and Paul L.H. McSweeney. Academic Press - Elsevier, London and Oxford, Ukand San Diego CA, USA.
- Minami, N., Yoshino, T., & Nakase, H. (2014). Unique endoscopic findings of colitis-associated colorectal cancer in a patient with ulcerative colitis and Lynch syndrome. *Journal of Crohn's & colitis* 8(4): 336–337. <https://doi.org/10.1016/j.crohns.2013.11.009>
- Montalban-Arques A, Scharl M. Intestinal microbiota and colorectal carcinoma: Implications for pathogenesis, diagnosis, and therapy. *EBioMedicine*. 2019/10/17. 2019 Oct;48:648–55.
- Mukaiida, N., Sasakki, So-ichiro & Popivanova B.K. (2011). Tumor Necrosis Factor (TNF) and Chemokines in Colitis-Associated Cancer. *Cancers review*. Vol. 3. Hal : 2811-2826. doi:10.3390/cancers3032811
- Murphy, N., Moreno, V., Hughes, D. J., Vodicka, L., Vodicka, P., Aglago, E. K., Gunter, M. J., & Jenab, M. (2019). Lifestyle and dietary environmental factors in colorectal cancer susceptibility. *Molecular aspects of medicine*, 69, 2–9. <https://doi.org/10.1016/j.mam.2019.06.005>
- Nerad, E., Lahaye, M. J., Maas, M., Nelemans, P., Bakers, F. C., Beets, G. L., & Beets-Tan, R. G. (2016). Diagnostic accuracy of CT for local staging of colon cancer: A systematic review and meta-analysis. *Am J Roentgenol*, 207(5), 984–95.
- Neurath, M. F., Fichtner-Feigl, S., & Kesselring, R. (2015). Intestinal Inflammation and Cancer of the Gastrointestinal Tract. *Mucosal Immunology*, 1761–1775. doi:10.1016/b978-0-12-415847-4.00091-4
- Ng, S. C., & Wong, S. H. (2013). Colorectal cancer screening in Asia. *British Medical Bulletin*, 105(1), 29–42. <https://doi.org/10.1093/bmb/lds040>
- Ngan, S. Y., Burmeister, B., Fisher, R. J., Solomon, M., Goldstein, D., Joseph, D., Ackland, S. P., Schache, D., McClure, B., McLachlan, S. A., McKendrick, J., Leong, T., Hartoepanu, C., Zalberg, J., & Mackay, J. (2012). Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. *J Clin Oncol*, 30(31), 3827–33.

- Nishitani, Y., Tanoue, T., Yamada, K., Ishida, T., Yoshida, M., Azuma, T., & Mizuno, M. (2009). *Lactococcus lactis* . cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice. *International Immunopharmacology*, 9(12), 1444–1451.
- Park, B. H., Kim, I. S., Park, J. K., Zhi, Z., Lee, H. M., Kwon, O. W., & Lee, B. C. (2021). Probiotic effect of *Lactococcus lactis* . cremoris RPG-HL-0136 on intestinal mucosal immunity in mice. *Appl Biol Chem*, 64(93). <https://doi.org/10.1186/s13765-021-00667-6>
- Pasparakis, M. (2009). Regulation of tissue homeostasis by NF- B signalling: implications for inflammatory diseases. *Nature Rev Immunology*, 9(11), 778- 788.
- Popat, S., & Houlston, R. S. (2005). A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. *Eur J Cancer*, 41(14), 2060–70.
- Pusat Data dan Informasi Kementerian Kesehatan RI. (2015). Situasi Penyakit Kanker. In *Buletin Jendela Data dan Informasi Kesehatan* (Vol. 1, Issue 2). <https://doi.org/10.1007/s12480-018-0030-x>
- Racadot E, Audhuy B, Duvernoy H, Thyss A, Lang JM, Wijdenes J and Hervé P. (1995). Clinical and immunological follow-up of patients with AIDS-associated Kaposi's sarcoma treated with an anti-IL-6 monoclonal antibody. *Cytokines Mol Ther* 1: 133-138.
- Raehann, N. R., Nurulita, A., & Arif, M. (2014). Carcinoembryonic Antigen (CEA) di Kanker Kolorektal. *Indonesian Journal of Clinical Pathology and Medical Laboratory*, 20(3), 192-195.
- Raskov, H., Burcharth, J., & Pommergaard, H. C. (2017). Linking gut microbiota to colorectal cancer. *J Cancer*, 8(17), 3378–95.
- Rawla, P., Sunkara, T., & Barsouk, A. (2019). Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. *Przegląd gastroenterologiczny*, 14(2), 89–103. <https://doi.org/10.5114/pg.2018.81072>
- Reddy, B. S. (2002). Animal Models for Colon Cancer Chemoprevention. *Encyclopedia of Cancer*, 49–55. doi:10.1016/b0-12-227555-1/00005-8
- Reiter, A., Bengesser, S. A., Hauschild, A. C., Birkl-Töglhofer, A. M., Fellendorf, F. T., Platzer, M., Färber, T., Seidl, M., Mendel, L. M., Unterweger, R., Lenger, M., Mörkl, S., Dalkner, N., Birner, A., Queissner, R., Hamm, C., Maget, A., Pilz, R., Kohlhammer-Dohr, A., Wagner-Skacel, J., ... Reininghaus, E. (2020). Interleukin-6 Gene Expression Changes after a 4-Week Intake of a Multispecies Probiotic in Major Depressive Disorder-Preliminary Results of the PROVIT Study. *Nutrients*, 12(9), 2575. <https://doi.org/10.3390/nu12092575>
- Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., Tu, D., Redston, M., & Gallinger, S. (2003). Tumor Microsatellite-

- Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer. *N Engl J Med*, 349(3), 247–57.
- Rolfe, R. D. (2000). Symposium : Probiotic Bacteria : Implications for Human Health The Role of Probiotic Cultures in the Control of Gastrointestinal Health 1. Fuller 1991, 396–402.
- Rossi, M., Jahanzaib Anwar, M., Usman, A., Keshavarzian, A., & Bishehsari, F. (2018). Colorectal Cancer and Alcohol Consumption-Populations to Molecules. *Cancers*, 10(2), 38. <https://doi.org/10.3390/cancers10020038>
- Sabit, H., Cevik, E., & Tombuloglu, H. (2019). Colorectal cancer: The epigenetic role of microbiome. *World journal of clinical cases*, 7(22), 3683–3697. <https://doi.org/10.12998/wjcc.v7.i22.3683>
- Sánchez-Alcoholado L, Ramos-Molina B, Otero A, Laborda-Illanes A, Ordóñez R, Medina JA, et al. The Role of the Gut Microbiome in Colorectal Cancer Development and Therapy Response. *Cancers (Basel)*. 2020 May;12.
- Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., Ribic, C., Grothey, A., Moore, M., Zaniboni, A., Seitz, J. F., Sinicrope, F., & Gallinger, S. (2010). Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. *J Clin Oncol*, 28(20), 3219–26.
- Sauer, R., Liersch, T., Merkel, S., Fietkau, R., Hohenberger, W., Hess, C., Becker, H., Raab, H. R., Villanueva, M. T., Witzigmann, H., Wittekind, C., Beissbarth, T., & Rödel, C. (2012). Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. *J Clin Oncol*, 30(16), 1926–33.
- Saus, E., Iraola-Guzmán, S., Willis, J. R., Brunet-Vega, A., & Gabaldón, T. (2019). Microbiome and colorectal cancer: Roles in carcinogenesis and clinical potential. *Molecular aspects of medicine*, 69, 93–106. <https://doi.org/10.1016/j.mam.2019.05.001>
- Sawicki, T., Ruszkowska, M., Danielewicz, A., Niedźwiedzka, E., Arłukowicz, T., & Przybyłowicz, K. E. (2021). A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. *Cancers*, 13(9), 2025. <https://doi.org/10.3390/cancers13092025>
- Sayuti, M., & Nouva, N. (2019). Kanker Kolorektal. *AVERROUS: Jurnal Kedokteran Dan Kesehatan Malikussaleh*, 5(2), 76. <https://doi.org/10.29103/averrous.v5i2.2082>
- Schirripa, M., Cohen, S. A., Battaglin, F., & Lenz, H. J. (2018). Biomarker-driven and molecular targeted therapies for colorectal cancers. *Semin Oncol*, 45(3), 124–32.

- Schmuck, R., Gerken, M., Teegen, E. M., Krebs, I., Klinkhammer-Schalke, M., Aigner, F., Pratschke, J., Rau, B., & Benz, S. (2020). Gender comparison of clinical, histopathological, therapeutic and outcome factors in 185,967 colon cancer patients. *Langenbeck's archives of surgery*, 405(1), 71–80. <https://doi.org/10.1007/s00423-019-01850-6>
- Scottish Intercollegiate Guidelines Network (SIGN). (2011). Diagnosis and management of colorectal cancer. SIGN publication no. 126. Edinburgh: SIGN.
- Sehgal, R., & Coffey, J. C. (2014). Historical development of mesenteric anatomy provides a universally applicable anatomic paradigm for complete/total mesocolic excision. *Gastroenterol Rep*, 2(4), 245–50.
- Shang, F. M., & Liu, H. L. (2018). *Fusobacterium nucleatum* and colorectal cancer: A review. *World J Gastrointest Oncol*, 10(3), 71–81.
- Sharma, A. (2019). Importance of Probiotics in Cancer Prevention and Treatment. *Recent Developments in Applied Microbiology and Biochemistry*. 33–45.
- Shaukat, A., Rector, T. S., Church, T. R., Lederle, F. A., Kim, A. S., Rank, J. M., & Allen, J. I. (2015). Longer Withdrawal Time Is Associated With a Reduced Incidence of Interval Cancer After Screening Colonoscopy. *Gastroenterology*, 149(4), 952–7.
- Siegel, R. L., Miller, K. D., Goding Sauer, A., Fedewa, S. A., Butterly, L. F., Anderson, J. C., Cercek, A., Smith, R. A., & Jemal, A. (2020). Colorectal cancer statistics, 2020. *CA Cancer J Clin*, 70(3), 145–64.
- Singh, N., Baby, D., Rajguru, J. P., Patil, P. B., Thakkannavar, S. S., & Pujari, V. B. (2019). Inflammation and cancer. *Annals of African medicine*, 18(3), 121–126. [https://doi.org/10.4103/aam.aam\\_56\\_18](https://doi.org/10.4103/aam.aam_56_18)
- Sivamaruthi, B. S., Kesika, P., & Chaiyasut, C. (2020). The Role of Probiotics in Colorectal Cancer Management. *Evidence-Based Complementary and Alternative Medicine*, 2020 <https://doi.org/10.1155/2020/3535982>
- Somasundaram, K., & El-Deiry, W. S. (2000). Tumor suppressor P53: Regulation and function. *Front Biosci*. 2000;(1):424–37.
- Stolfi, C., Troncione, E., Marafini, I., & Monteleone, G. (2021). Role of TGF- $\beta$  and smad7 in gut inflammation, fibrosis and cancer. *Biomolecules*, 11(1), 1–15. <https://doi.org/10.3390/biom11010017>
- Sukma, A., Toh, H., Nguyen, T. T. T., Fitria, N., Mimura, I., Kaneko, R., Arakawa, K., & Morita, H. (2018). Microbiota community structure in traditional fermented milk dadiah in Indonesia: Insights from high-throughput 16S rRNA gene sequencing. *Milk Science International*, 71(1), 1–3.
- Soleimani,Atena., Pashirzad, Mehran., Avan, Amir.,Ferns, Gordon A., et al. (2019). Role of transforming growth factor  $\beta$  signaling pathway in the

pathogenesis of colorectal cancer . Journal of Cellular Biochemistry.120:8899-8907

- Søndena, K., Quirke, P., Hohenberger, W., Sugihara, K., Kobayashi, H., Kessler, H., Brown, G., Tudyka, V., D'Hoore, A., Kennedy, R. H., West, N. P., Kim, S. H., Heald, R., Storli, K. E., Nesbakken, A., & Moran, B. (2014). The rationale behind complete mesocolic excision (CME) and a central vascular ligation for colon cancer in open and laparoscopic surgery: Proceedings of a consensus conference. *Int J Colorectal Dis*, 29(4), 419–28.
- Tang K, Kong D, Peng Y, et al. (2022). Ginsenoside Rc attenuates DSS-induced ulcerative colitis, intestinal inflammatory, and barrier function by activating the farnesoid X receptor. *Front Pharmacol*, 13:1000444.
- Taieb, J., Le Malicot, K., Shi, Q., Penault-Llorca, F., Bouché, O., Taberero, J., Mini, E., Goldberg, R. M., Folprecht, G., Luc Van Laethem, J., Sargent, D. J., Alberts, S. R., Emile, J. F., Laurent Puig, P., & Sinicrope, F. A. (2016). Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. *J Natl Cancer Inst*, 109(5), djw272.
- Tie Y, Tang F, Peng D, Zhang Y, Shi H. (2022). TGF- $\beta$  signal transduction: biology, function and therapy for diseases. *Mol Biomed*, 3(1). <https://doi.org/10.1186/s43556-022-00109-9>
- Toma, M., Belușică, L., Stavarachi, M., Apostol, P., Spandole, S., Radu, I., & Cimponeriu, D. (2012). Rating the environmental and genetic risk factors for colorectal cancer. *Journal of Medicine and Life*, 5(Spec Issue), 152–159.
- Tsai Y-L, Lin T-L, Chang C-J, Wu T-R, Lai W-F, Lu C-C, et al. Probiotics, prebiotics and amelioration of diseases. *J Biomed Sci*. 2019 Jan;26:3.
- Tyler, J. A., Fox, J. P., Desai, M. M., Perry, W. B., & Glasgow, S. C. (2013). Outcomes and costs associated with robotic colectomy in the minimally invasive era. *Dis Colon Rectum*, 56(4), 458–66.
- Usmiati, R., & Risfaheri. (2013). Pengembangan Dadih Sebagai Pangan Fungsional Probiotik Asli Sumatera Barat. *J. Litbang Pert*, 32(1), 20–29. <https://doi.org/10.21082/jp3.v32n1.2013.p20-29>
- Vaghari-Tabari M, Targhazeh N, Moei, S, Qujeq D, et al. (2022). From Inflammatory bowel disease to colorectal cancer: what's the role of miRNAs?. *Cancer cell international* 22: 146.
- Valentini, V., Aristei, C., Glimelius, B., Minsky, B. D., Beets-Tan, R., Borrás, J. M., Haustermans, K., Maingon, P., Overgaard, J., Pahlman, L., Quirke, P., Schmoll, H. J., Sebag-Montefiore, D., Taylor, I., Van Cutsem, E., Van de Velde, C., Cellini, N., Latini, P., & Scientific Committee. (2009). Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). *Radiother Oncol*, 92(2), 148–63. doi: 10.1016/j.radonc.2009.06.027.
- van der Pas, M. H., Haglind, E., Cuesta, M. A., Fürst, A., Lacy, A. M., Hop, W. C., Bonjer, H. J., & COLOrectal cancer Laparoscopic or Open Resection II

- (COLOR II) Study Group. (2013). Laparoscopic versus open surgery for rectal cancer (COLOR II): Short-term outcomes of a randomised, phase 3 trial. *Lancet Oncol*, 14(3), 210–218.
- Vanderpool, C., Yan, F., & Polk, D. B. (2008). Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases. *Inflamm Bowel Dis*, 14(11), 1585–96.
- van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, et al. (2014). Siltuximab for multicentric Castleman's disease: A randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 15:966-974.
- Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Nakamura, Y., White, R., Smits, A. M., & Bos, J. L. (1988). Genetic Alterations During Colorectal-Tumor Development. *N Engl J Med*, 319(9), 525-532.
- Viennois, E., Chen, F., & Merlin, D. (2013) . NF- $\kappa$ B pathway in colitis-associated cancers. *Transl Gastrointest Cancer*, 2(1), 21–29. <https://doi.org/10.3978/j.issn.2224-4778.201211.01>.
- Waldner, M. J., Foersch, S., & Neurath, M. F. (2012). Interleukin-6--a key regulator of colorectal cancer development. *International journal of biological sciences*, 8(9), 1248–1253. <https://doi.org/10.7150/ijbs.4614>
- Waly, Mustafa i., Al Rawahi, Amani S., Riyami, Marwa Al., Alkindi, Mohammed A, et al. (2014) Amelioration of Azoxymethane induced Carcinogenesis by reducing oxidative stress in rat colon by natural extract. *BMC Complimentary and Alternative Medicine* 14: 60.
- Wang, S., Liu, Z., Wang, L., & Zhang, X. (2009). NF- B signaling Pathway, inflammation and colorectal cancer. *Cellular & Molecular Immunology*, 6(5), 327-34.
- Wang T, Song P, Zhong T, Wang X, Xiang X, Liu Q, Chen H, Xia T, Liu H, Niu Y, Hu Y, Xu L, Shao Y, Zhu L, Qi H, Shen J, Hou T, Fodde R, Shao J. (2019). The inflammatory cytokine IL-6 induces FRA1 deacetylation promoting colorectal cancer stem-like properties. *Oncogene*, 38(25):4932-4947.
- Wang T, Zhang L, Wang P, Liu Y, Wang G, Shan Y, Yi Y, Zhou Y, Liu B, Wang X, Lü X. (2021). *Lactobacillus coryniformis* MXJ32 administration ameliorates azoxymethane/dextran sulfate sodium-induced colitis-associated colorectal cancer via reshaping intestinal microenvironment and alleviating inflammatory response. *Eur J Nutr*, 61(1):85-99.
- Wieczorska, K., Stolarek, M., & Stec, R. (2020). The Role of the Gut Microbiome in Colorectal Cancer: Where Are We? Where Are We Going?. *Clinical colorectal cancer*, 19(1), 5–12. <https://doi.org/10.1016/j.clcc.2019.07.006>
- Wirawati, C. U., Sudarwanto, M., Lukman, D., & Wientarsih, D. I. (2017). Karakteristik dan Pengembangan Dadih dari Susu Sapi sebagai Alternatif

- Dadih Susu Kerbau (Characteristic and Development of Cow's Milk Dadih as an Alternate of Buffalo's Milk Dadih). *Wartazoa*, 27(2), 95–103. <http://dx.doi.org/10.14334/wartazoa.v27i2.1595>.
- Wong, K., & Xie, G. (2017). Updates on the Molecular Genetics of Colorectal Cancer. *Colorectal Cancer: Open Access*, 03(01), 1–8. <https://doi.org/10.21767/2471-9943.100032>
- Wong, S. H., & Yu, J. (2019). Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. *Nature reviews. Gastroenterology & hepatology*, 16(11), 690–704. <https://doi.org/10.1038/s41575-019-0209-8>
- Wouters, J. T. M., Ayad, E. H. E., Hugenholtz, J., & Smit, G. (2002). Microbes from raw milk for fermented dairy products. *International Dairy Journal*, 12(2–3), 91–109. [https://doi.org/10.1016/S0958-6946\(01\)00151-0](https://doi.org/10.1016/S0958-6946(01)00151-0)
- Wu, S., Rhee, K. J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H. R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., Housseau, F., Pardoll, D. M., & Sears, C. L. (2009). A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. *Nat Med*, 15(9), 1016–22.
- Xu, W., Liu, L., Loizidou, M., Ahmed, M., & Charles, I. G. (2002). The role of nitric oxide in cancer. *Cell Res*, 12(5-6), 311–320. <https://doi.org/10.1038/sj.cr.7290133>
- Young, A., & Rea, D. (2000). ABC of colorectal cancer treatment of advanced disease. *BMJ*, 321(7271), 1278-81.
- Yu, Wei., Su, xing., Tian, xing., Zhang, ke. Guo, gang., et al. (2019) Three types of gut bacteria collaborating to improve KuinJie'an enema treat DSS induced colitis in Mice. *Biomedicine & pharmacotherapy*. 11310875
- Yu, H., Lin, L., Zhang, Z., Zhang, H., & Hu, H. (2020). Targeting NF- $\kappa$ B pathway for the therapy of diseases: mechanism and clinical study. *Signal transduction and targeted therapy* 5(1): 209. <https://doi.org/10.1038/s41392-020-00312-6>
- Yu H, Dai C, Zhu W, Jin Y, Wang C. (2022). PFKFB3 Increases IL-1 $\beta$  and TNF- $\alpha$  in Intestinal Epithelial Cells to Promote Tumorigenesis in Colitis-Associated Colorectal Cancer. *J Oncol*, 2022:6367437.
- Yue Y, Ye K, Lu J, Wang X, Zhang S, Liu L, Yang B, Nassar K, Xu X, Pang X, Lv J. (2020). Probiotic strain *Lactobacillus plantarum* YYC-3 prevents colon cancer in mice by regulating the tumour microenvironment. *Biomed Pharmacother*, 127:110159.
- Yuniastuti, A. (2014). *Probiotik (Dalam Perspektif Kesehatan)*. Semarang: Unnes Press. hal 100.
- Zaharuddin, L., Mokhtar, N. M., Muhammad Nawawi, K. N., & Raja Ali, R. A. (2019). A randomized double-blind placebo-controlled trial of probiotics in



- post-surgical colorectal cancer. *BMC Gastroenterology*, 19(1), 131. <https://doi.org/10.1186/s12876-019-1047-4>
- Zahirović A, Berlec A. (2022). Targeting IL-6 by engineered *Lactococcus lactis* via surface-displayed affibody. *Microb Cell Fact*, 21(1):143.
- Zahirović A, Plavec TV, Berlec A. (2022). Dual Functionalized *Lactococcus lactis* Shows Tumor Antigen Targeting and Cytokine Binding in Vitro. *Front Bioeng Biotechnol*, 10:822823.
- Zauber, A. G., Knudsen, A. B., Rutter, C. M., Lansdorp-Vogelaar, I., Savarino, J. E., van Ballegooijen, M., & Kuntz, K. M. (2009). Cost-Effectiveness of CT Colonography to Screen for Colorectal Cancer. Agency for Healthcare Research and Quality (US).
- Zhang, B., Li, A., Zuo, F., Yu, R., Zeng, Z., Ma, H., & Chen, S. (2016). Recombinant *Lactococcus lactis* NZ9000 secretes a bioactive kisspeptin that inhibits proliferation and migration of human colon carcinoma HT-29 cells. *Microbial cell factories*, 15(1), 102. <https://doi.org/10.1186/s12934-016-0506-7>
- Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. (2021). Inflammation and tumor progression: signaling pathways and targeted intervention. *Signal Transduct Target Ther*, 6(1):263.
- Zhen, Y., Luo, C., & Zhang, H. (2018). Early detection of ulcerative colitis-associated colorectal cancer. *Gastroenterology report*, 6(2), 83–92. <https://doi.org/10.1093/gastro/goy010>

